HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19.

HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19.

Authors

  • Giorgio Ciprandi Consultant Allergist, Casa di Cura Villa Montallegro, Genoa, Italy
  • Luisa Maria Bellussi International Federation ORL Societies (IFOS) Executive Board members Rome Italy
  • Valerio Damiani Medical Department, DMG Italia, Rome, Italy.
  • Desiderio Passali International Federation ORL Societies (IFOS) Executive Board members Rome Italy

Keywords:

COVID-19, SARS CoV-2, HMGB1, Glycyrrhizin, Prophylaxis.

Abstract

The COVID-19 pandemic era is causing a relevant issue for the health. There is no specific drug able to antagonize the SARS-CoV-2 infection. As a consequence, there is growing interest about potential molecules able to contrast infection. In this regard, HMGB, an alarmin, may play a relevant role in pathogenic mechanisms induced by SARS-CoV-2.  As HMGB1 is antagonized by glycyrrhizin, this substance could be potentially useful as ancillary treatment in COVID-19.

References

WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324(8):782-793

Marmitt DJ, Goettert MI, Rempel C. Compounds of plants with activity against SARS-CoV-2 targets. Expert Rev Clin Phrmacol 2021 (in press)

Omrani M, Keshavarz M, Ebrahimi SN, Mehrabi M, McGraw LJ, Abdalla MA, et al. Potential natural products against respiratory viruses. A prespective to develop anti-COVID-19 medicines. Frontiers Pharmacol 2021;11:586993

Qu L, Chen C, Chen Y, Li Y, Tang F, Huang H, et al. High-mobility group box 1 (HMGB1) and autophagy in acute lung injury (ALI): a review. Med Sci Monit 2019;25:1828-1837

Yang H, Wang H, Andersson U. Targeting inflammation driven by HMGB1. Frontiers Immunol 2020;11:484

Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med 2020;26:42

Chiappalupi S, Salvadori L, Vukasinovic A, Donato R, Sorci G, Riuzzi F. Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: hypotheses and perspectives. Life Sci 2021;272:119251

Chen R, Huang Y, Quan J, Liu J, Wang H, Billiar TR, et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon 2020;6:e05672

Bailly C, Vergoten G. Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Therap 2020;214:107618

Kwon YJ, Son DH, Chung TH, Lee YJ. A review of the pharmacological efficacy and safety of Licorice root from corroborative clinical trial findings. J Med Food 2010;23.1-9

Richard SA. Exploring the pivotal immunomodulatory and anti-inflammatory potentials of glycyrrhizic and glycyrrhetinic acids. Mediators Inflamm 2021;6699560

El-Saber Batiha G, Beshbishy AM, El-Mleeh A, Abdel-Daim MM, Prasad Devkota H. Traditional uses, bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules 2020;10:352

Murck H. Symptomatic protective action of glycyrrhizin (Licorice) in COVID-19 infection? Frontiers Immunol 2020;11:1239

Luo P, Liu D, Li J. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents 2020;55.105995

Downloads

Published

01-10-2021

How to Cite

1.
Ciprandi G, Bellussi LM, Damiani V, Passali D. HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19. . Acta Biomed [Internet]. 2021 Oct. 1 [cited 2024 Jul. 24];92(S6):e2021455. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/12111